CLINICAL_TRIALS
ClinicalTrials.gov record update
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in Transitional Liver Cell Tumors（TLCT）and Refractory Hepatoblastoma for Young Adolescent and Pediatric Participants After Chemotherapy：a Cohort Study
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05322187
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:43.231132+00:00
- Published At
- 2022-04-11T00:00:00+00:00
- Record Updated At
- 2022-04-11
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Transitional Cell Tumor", "Hepatoblastoma", "Liver Cancer", "Pediatric Solid Tumor", "Pediatric Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-04-11"- protocolSection.identificationModule.nctId
"NCT05322187"- protocolSection.identificationModule.officialTitle
"Sequential PD-1/PD-L1 Inhibitor and LENvatinib in Transitional Liver Cell Tumors\uff08TLCT\uff09and Refractory Hepatoblastoma for Young Adolescent and Pediatric Participants After Chemotherapy\uff1aa Cohort Study"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE2", "PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.